Business Wire

Merz Delivers Double-Digit Growth in Strategic Business Areas

Share

Merz, a global leader in aesthetics and neurotoxins, showed substantial growth across both of its strategic focus areas at the end of its most recently completed fiscal year 2017/18. Merz’s aesthetics and specialty neurology businesses both increased by 19 percent versus prior year, excluding foreign exchange impact. Together, these two areas now account for 67 percent of the company’s healthcare revenue.

“Merz has continued to strengthen its position as a leader in the fields of medical aesthetics and neurotoxin therapy. A combination of focused investment in these core business areas, along with a clear global strategy and excellent execution across all regions, has enabled Merz to compensate for the anticipated decrease in licensing income and to successfully transform our business for growth in the years to come,” said Philip Burchard, Chief Executive Officer of Merz Group.

The Frankfurt-based company reported total revenue of EUR 1,024 million in fiscal year 2017/18 (previous year: EUR 1,023 million). Merz’s healthcare revenue increased 12 percent – excluding foreign exchange impact – to EUR 902 million (previous year: EUR 862 million), and the shift toward core business areas continues, in line with the company’s strategy. The regional structure of Merz’s business continues to generate strong performance across all geographies. EMEA (Europe, Middle East and Africa) and North America remain Merz’s largest regions in terms of revenue contribution, with the strongest growth rates coming from the emerging market economies of Asia Pacific and Latin America.

Merz reported earnings before interest and tax (EBIT) of EUR 93 million for fiscal year 2017/18. As anticipated, this number represents a decrease of 6 percent versus the prior year figure of EUR 99 million, due to the loss of licensing income from Merz’s Alzheimer’s disease drug memantine. As forecasted, overall licensing income from memantine continued to fall due to expiration of patent protection in a majority of markets worldwide, including the U.S. Licensing income declined to EUR 122 million (previous year: EUR 162 million) and accounted for only 12 percent of Merz’s overall revenue in fiscal year 2017/18.

As of June 30, 2018, Merz had a total workforce of 3,151 employees (prior year: 2,997), the majority of which are employed in Germany and the United States.

Research and development activities
In fiscal year 2017/18, Merz invested EUR 128 million in research and development activities, which represented 13 percent of the company’s total annual revenue and a slight decrease from the prior year’s expenditures of EUR 147 million.

110 years of innovation, commitment and trust
In March 2018, Merz celebrated the 110-year anniversary of the company’s founding in Frankfurt by German pharmacist and chemist Friedrich Merz. The company has remained family-owned since its founding in 1908 and continues to benefit from the long-term perspective and full support of its Shareholders` Council and Supervisory Board, which include members of the fourth-generation of the Merz family.

Michael von Truchseß has announced that he is retiring from his position as Member of the Supervisory Board and the Shareholders’ Council of Merz Pharma GmbH & Co. KGaA. Effective October 18, 2018, Dr. Christian Holzherr, already member of the Supervisory Board, will also become a member the Shareholders’ Council. Dr. Holzherr is a highly experienced finance executive with a track record of CEO and CFO positions in the pharmaceutical and medical device industries. “We would like to take this opportunity to sincerely thank Mr. von Truchseß for his many years of service and counsel to Merz, and to wish him well in his retirement,” said Andreas Krebs, Chairman of the Supervisory Board and the Shareholders’ Council.

Outlook for fiscal year 2018/19
On July 3, 2018, Merz’s neurotoxin Xeomin® (incobotulinumtoxinA) received approval for the treatment of sialorrhea in adult patients from the US Food and Drug Administration (FDA), making Xeomin® (incobotulinumtoxinA) the first neurotoxin globally to receive an approval for this indication. European marketing authorization approval for this indication is anticipated in the first half of 2019.

As of September 2018, Merz has combined its business in North America and Latin America to create a new Americas Region, under the leadership of Bob Rhatigan as CEO – Americas. This fiscal year, Merz expects to strengthen its presence in both geographies, which are home to some of the world’s top aesthetics markets and represent more than half of the total aesthetic procedures performed globally each year.1

“Although we plan for increased competition in the aesthetics injectables space in fiscal year 2018/19 due to additional market entrants in Europe and the US, Merz expects to see profitable growth and strong financial performance in the coming year across all regions,” said Philip Burchard.

About Merz
Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately-held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products across the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2017/18, Merz generated revenue of EUR 1.024,4 million; the company has a total workforce of 3,151 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com.

1 Source: Global market research data on file

Contact information

Media Contact
Merz Pharma GmbH & Co. KGaA
Global Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Slate Asset Management Announces Minority Investment From Goldman Sachs Asset Management’s Petershill Program19.8.2019 15:00:00 EESTPress release

Slate Asset Management L.P. (Slate), a leading alternative asset management platform with a focus on real estate and real assets, today announced a passive, non-voting minority equity investment from Goldman Sachs Asset Management’s Petershill program, creating a strategic relationship with one of the world’s leading investment managers and positioning Slate for future success. The transaction will have no impact on the control or decision making of Slate. The day-to-day operations and management of Slate will remain unchanged. The investment provides capital that Slate will use to enhance its platform and increase its GP investments in current and future businesses and investment vehicles, further strengthening the firm’s alignment with its clients and investing partners. The investment accelerates Slate’s goal to build the leading independent alternative investment platform in real estate and real assets. As part of the transaction, Slate Founders Blair and Brady Welch have made a lo

OpenGate Capital Announces Acquisition of Majority Interest in InRule Technology, Inc.19.8.2019 15:00:00 EESTPress release

OpenGate Capital, a global private equity firm, announced today that it has acquired InRule Technology, Inc. (“InRule”), a market-leading decision management platform and business rules management system (BRMS). OpenGate is pleased to partner with the co-founders of InRule to continue innovation and leadership in the decision management market. This transaction marks the fifth investment completed in 2019 through OpenGate Capital’s second institutional fund. Financial terms were not disclosed. InRule software powers mission-critical decisions for enterprise and government customers. InRule provides an end-to-end, fully auditable platform that acts as a “single source of truth” for enterprises processing complex business rules and decision workflows. Its decision platform drives significant and quantifiable business value across a variety of use cases, including insurance eligibility, mortgage qualification, risk rating and fraud reduction, regulatory compliance, healthcare claims proce

Cogeco Peer 1 Changes Name to Aptum Technologies; Adds New Services to Enhance and Expand Hybrid Cloud Offerings19.8.2019 15:00:00 EESTPress release

Cogeco Peer 1, a managed hosting and cloud services provider, today announced it has changed its name to Aptum Technologies. The move follows the April 2019, acquisition of Cogeco Peer 1 by Digital Colony, a global investment firm dedicated to strategic opportunities in digital infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190819005121/en/ Susan Bowen, CEO of Aptum (Photo: Business Wire) “Aptum means ‘adaptability’ and reflects our heritage and vision for the future,” said Susan Bowen, Chief Executive Officer of Aptum. “As businesses face exponentially increasing volumes of information, and data becomes an integral part of their infrastructure, technology platforms must adapt and harness the power of data to enable better decision making, risk evaluation and customer engagement. We help organizations unlock the potential of their data by providing a robust infrastructure that enables customers to solve compl

Advantage Smollan has Acquired Majority Ownership of WorkShop19.8.2019 14:00:00 EESTPress release

Advantage Smollan, the joint holding company between Advantage Solutions and Global Smollan Holdings has acquired a majority ownership interest in WorkShop International. WorkShop is the leading retail agency in the Nordics with an impressive client list consisting of many of the world’s most successful and sought-after brands within retail. Since 2016, the company has successfully branched out internationally by widening its service offerings across the Nordics and Holland. The investment by Advantage Smollan is yet another step towards meeting the demand for strategic, creative and tactical retail initiatives in several markets. “We are enthusiastic about WorkShop joining Advantage Smollan," said Laurence Clube, Chief Operating Officer of Advantage Smollan. "Our investment brings another high-quality business into the group, further expanding our geographical reach in line with our vision to improve and broaden our range of services for our customers.” "Advantage Smollan’s strategy i

Knopp Biosciences Announces Start of Phase 2 Clinical Trial Evaluating Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma19.8.2019 13:00:00 EESTPress release

Knopp Biosciences LLC today announced the start of Phase 2 dose-ranging clinical trial in moderate-to-severe eosinophilic asthma. Recruitment in the trial is underway and the first patient has been enrolled. The Company anticipates reporting top-line data from this trial in the second half of 2020. This 12-week biomarker study is planned to randomize approximately 100 patients with eosinophilic asthma to investigate the eosinophil response to three different doses of oral dexpramipexole. The primary outcome measure of this randomized, double-blind, placebo-controlled study is the change in blood absolute eosinophil count from Baseline to Week 12. The secondary outcome measures include changes in pre-bronchodilator FEV1 and asthma control outcomes (ACQ-7 questionnaire) from baseline to week 12. “We estimate that there are more than two million moderate-to-severe eosinophilic asthma patients in the U.S. and are excited about further characterizing the clinical profile of oral dexpramipex

CES Unveiled in Amsterdam to Showcase Tech for Good19.8.2019 10:00:00 EESTPress release

Consumer Technology Association (CTA): WHAT: The Consumer Technology Association (CTA)® today announced several government officials, dignitaries and industry leaders attending CES Unveiled in Amsterdam, an official CES preview event, focusing on the theme “Tech for Good.” Returning for its third year, CES Unveiled in Amsterdam will bring together executives, influential media, prominent industry influencers, and more than 100 companies (including 50+ startups) to explore the latest technology trends and innovations from the Netherlands and surrounding European countries leading up to CES® 2020. Attendees and media are able to register for CES Unveiled in Amsterdam online. WHO: Government officials and dignitaries including Mona Keijzer, Netherlands State Secretary for Economic Affairs and Climate Policy; HRH Prince Constantijn van Oranje, Special Envoy at TechLeap.NL; and Pete Hoekstra, U.S. Ambassador to the Netherlands, will share insights on emerging trends in the industry, includi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom